semaglutide intestinal issues Benefits of GLP-1 Gastrointestinal adverse events associated with

While human studies on semaglutide during pregnancy are limited, animal studies suggest an increased risk of miscarriage and birth defects

The key challenge is determining whether this represents a true drug-related risk or reflects confounding factors among patients who are more likely to receive semaglutide

Candidates for GLP1 weight loss medications typically have a body mass index (BMI) in the overweight or obese range and may have weightrelated health concerns such as prediabetes, type 2 diabetes, high blood pressure, or elevated cholesterol

Additionally, the defense sought discovery and motion practice on general causationspecifically, whether GLP-1RAs can cause intestinal and bowel injuries as alleged in the Ozempic lawsuits